拉丁美洲的风湿性关节炎:药物治疗和临床挑战
Enrique R Soriano1, Eduardo Mysler2, Carlos Rios3
1Rheumatology Section, Hospital Italiano de Buenos Aires and University Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Expert opinion on pharmacotherapy
|October 4, 2024
概括
拉丁美洲的类风湿性关节炎 (RA) 管理面临诸如不一致的治疗准入和专家短缺等障碍. 改善药物获取和培训对于改善该地区患者的治疗结果至关重要.
科学领域:
- 类风湿病学 类风湿病学
- 拉丁美洲医疗保健系统
- 流行病学 流行病学
背景情况:
- 类风湿性关节炎 (RA) 在拉丁美洲 (LA) 提出了独特的管理挑战,因为其高患病率和特定的医疗保健动态.
- 尽管全球取得了进展,但LA在有效控制RA方面面临着明显的障碍.
- 了解这些区域因素对于推进RA护理至关重要.
研究的目的:
- 审查LA地区RA的流行病学.
- 检查当前的RA治疗策略及其可访问性.
- 确定影响该地区RA患者护理的关键临床挑战.
主要方法:
- 在LA的RA流行病学的文献综述.
- 对治疗指南和药物可获得性的分析 (csDMARDs,生物制剂,生物类似药).
- 识别护理障碍,包括专家短缺和社会经济因素.
主要成果:
- 在LA地区,RA的患病率各不相同,土著人口的患病率更高.
- 获得推疗法,包括常规合成疾病修饰性抗风湿药物 (csDMARDs) 和先进治疗方法,是不一致的.
- 显著的障碍包括药物供应中断,诊断延迟,遵守率低,以及风湿病学家短缺.
结论:
- 虽然LA的RA护理有所改善,但仍然存在重大挑战,包括专家短缺和分散的医疗保健.
- 加强医疗教育,扩大远程医疗,确保药物供应的一致性至关重要.
- 加强临床研究和改善获得负担得起的治疗方法的机会对于弥合护理差距至关重要.
相关概念视频
01:21Rheumatic Heart Disease III: Medical Management
3
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
3
01:28Drug Therapy
39
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
39
01:29Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
01:20Rheumatic Heart Disease IV: Nursing Management
5
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
5
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
8
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
8
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143